Myelofibrosis: Clinical Trials

87 trials for Myelofibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 17 recruiting, 16 terminated, 11 active not recruiting. 87 Phase 1, 31 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 187Completed 32, Recruiting 17, Terminated 16, Active not recruiting 11, Unknown 6, Withdrawn 4, Not yet recruiting 1
Phase 231Completed 11, Recruiting 8, Terminated 6, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis

Trials (filtered) newest first · largest first

All 87 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Revumenib in Patients With Myelofibrosis
Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1 / Phase 2Not yet recruitingJohn Mascarenhas322026-12-012026-07-29
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Phase 1RecruitingCity of Hope Medical Center462026-09-092026-10-23
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis
Phase 1RecruitingUniversity of Utah152026-08-212026-10-19
QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis
Phase 1Active not recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.602026-07-302026-08-07
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis
Phase 1Active not recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.172026-07-202026-07-27
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
rebecsinib - Secondary AML, Myelofibrosis
Phase 1RecruitingAspera Biomedicines, Inc.282026-05-212026-07-20
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
TQ05105 - Myelofibrosis
Phase 1RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.242026-04-012026-04-06
Momelotinib During and After HCT in Myelofibrosis
Momelotinib - Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Phase 1RecruitingMassachusetts General Hospital282026-02-232026-03-31
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
Nelfinavir - Myelofibrosis, Myelofibrosis; Anemia
Phase 1 / Phase 2RecruitingUniversity of California, Irvine102025-09-162026-10-26
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
Tasquinimod - Myelofibrosis
Phase 1 / Phase 2RecruitingStichting Hemato-Oncologie voor Volwassenen Nederland202025-02-202025-03-07
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Ulixertinib, Ruxolitinib - Myelofibrosis
Phase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center372025-01-072026-07-28
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
TQ05105 - Myelofibrosis
Phase 1CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.322024-10-122025-08-24
A Safety and Tolerability Study of Jaktinib
Jaktinib Hydrochloride Tablet - Myelofibrosis
Phase 1UnknownSuzhou Zelgen Biopharmaceuticals Co.,Ltd262024-07-012024-03-21
A Study of GLB-001 in Patients With Myeloid Malignancies
GLB-001 - Polycythemia Vera, Essential Thrombocythemia
Phase 1RecruitingHangzhou GluBio Pharmaceutical Co., Ltd.1082024-05-242025-08-19
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
TQ05105 tablets, TQB3909 tablets - Myelofibrosis
Phase 1 / Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.212024-05-132026-01-05
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
TQ05105 Tablets, TQB3617 Capsules - Myelofibrosis
Phase 1 / Phase 2RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.922023-12-122025-12-08
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions
Jaktinib Hydrochloride Tablets - Myelofibrosis
Phase 1CompletedSuzhou Zelgen Biopharmaceuticals Co.,Ltd522023-11-292024-01-11
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule - Myelofibrosis
Phase 1CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.402023-09-212025-12-12
AlloHCT With PegINFa for Myelofibrosis
Pegylated interferon alpha2a - Myelofibrosis
Phase 1RecruitingUniversity of Utah182023-08-022026-10-27
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia
Phase 1Active not recruitingMarina Kremyanskaya72023-04-042026-09-28

Showing 20 of 87. Sign in to see all of them.

Narrower conditions

Primary Myelofibrosis (87)  ·  Myelodysplastic Syndromes (20)  ·  Leukemia, Myeloid, Acute (19)  ·  Myeloproliferative Disorders (18)  ·  Polycythemia Vera (12)  ·  Thrombocythemia, Essential (12)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (10)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (9)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9)  ·  Leukemia, Myelomonocytic, Chronic (9)  ·  Lymphoma, Non-Hodgkin (9)  ·  Hodgkin Disease (6)  ·  Lymphoma (6)  ·  Multiple Myeloma (6)  ·  Hematologic Neoplasms (5)

Broader conditions

Hemic and Lymphatic Diseases (87)  ·  Bone Marrow Diseases (85)  ·  Hematologic Diseases (84)  ·  Myeloproliferative Disorders (69)  ·  Neoplasms (40)  ·  Neoplasms by Histologic Type (29)  ·  Leukemia, Myeloid (24)  ·  Leukemia (23)  ·  Disease Attributes (22)  ·  Pathologic Processes (22)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Chronic Disease (21)  ·  Neoplasms by Site (20)  ·  Hemorrhagic Disorders (18)  ·  Immune System Diseases (18)

Interventions

ruxolitinib (24)  ·  11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (5)  ·  fedratinib (4)  ·  fludarabine (4)  ·  Busulfan (3)  ·  Decitabine (3)  ·  N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (3)  ·  Stem Cell Transplantation (3)  ·  Azacitidine (2)  ·  Cyclophosphamide (2)  ·  Injections (2)  ·  Methotrexate (2)  ·  Mycophenolic Acid (2)  ·  NIS-793 (2)  ·  Tacrolimus (2)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9)  ·  Novartis Pharmaceuticals (4)  ·  Incyte Corporation (3)  ·  John Mascarenhas (3)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3)  ·  Bristol-Myers Squibb (2)  ·  CTI BioPharma (2)  ·  City of Hope Medical Center (2)  ·  Kartos Therapeutics, Inc. (2)  ·  M.D. Anderson Cancer Center (2)  ·  S*BIO (2)  ·  University of California, Irvine (2)  ·  University of Utah (2)  ·  American Regent, Inc. (1)  ·  Asana BioSciences (1)

Countries

United States (62)  ·  Germany (15)  ·  Italy (15)  ·  China (14)  ·  Australia (10)  ·  France (10)  ·  United Kingdom (9)  ·  Canada (8)  ·  Spain (8)  ·  Netherlands (6)  ·  Poland (5)  ·  Austria (3)  ·  Israel (3)  ·  South Korea (3)  ·  Belgium (2)

Top investigators

Ayalew Tefferi, MD (3)  ·  John Mascarenhas, MD (3)  ·  Ronald Hoffman, MD (2)  ·  Andrea Bacigalupo, MD (1)  ·  Andrew Roberts, M.D. (1)  ·  Angela Fleischman, MD, PhD (1)  ·  Angela Flesichman, MD, PhD (1)  ·  Anthony M Hunter, MD (1)  ·  Bik To, MD (1)  ·  Camelia Iancu-Rubin, PhD (1)  ·  Camille Abboud, M.D. (1)

Results publications

PMID 20843246, PMID 22718840, PMID 23682558, PMID 24355079, PMID 25563429, PMID 25762180, PMID 27931243, PMID 29544547, PMID 30249277, PMID 31778911, PMID 32396615, PMID 33718228, PMID 36105914, PMID 36125208, PMID 36594185, PMID 36881782, PMID 37530627, PMID 38259250, PMID 39924599, PMID 40241543, PMID 40334082, PMID 40752760, PMID 40919483, PMID 41146971, PMID 41758981, PMID 42054549, PMID 42855460

NIH funding

2018 (3), 2019 (3), 2023 (2), P01CA108671 (2), 2014 (1), 2015 (1), P01CA229092 (1), P30CA033572 (1), P50CA100632 (1)